OSAKA, Japan & CAMBRIDGE, Mass. — (BUSINESS WIRE) — Takeda (TSE:4502/NYSE:TAK) today presented four abstracts including interim real-world data from the observational Phase 4 EMPOWER s…
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
OSAKA, Japan & CAMBRIDGE, Mass. — (BUSINESS WIRE) — Takeda (TSE:4502/NYSE:TAK) today presented four abstracts including interim real-world data from the observational Phase 4 EMPOWER s…